M55 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improving Revenue TrendRevenue has improved to approximately $167.7 million and growth accelerated to about 6.7%, while the net margin improved substantially from the prior year. This indicates better operating momentum and cost or mix discipline, although profitability has not yet been reached.
Reduced LeverageThe sharp reduction in debt-to-equity indicates improved leverage relative to 2025, while total debt remains about $35.1 million. This gives MacroGenics a more manageable capital structure and greater financial flexibility as it advances its clinical pipeline.
Advancing Oncology PipelineInitiating human dosing for MGC030 expands MacroGenics’ clinical-stage oncology pipeline and provides another potential development asset. Continued advancement of antibody-drug conjugates can strengthen the company’s platform credibility and create future partnering or milestone opportunities.
Bears Say
Persistent Cash BurnOperating and free cash flow remain deeply negative, showing that the business is still consuming substantial cash despite narrower losses. Continued cash burn can require additional financing or partnering proceeds and may constrain the pace of investment in clinical programs.
Unprofitable OperationsMacroGenics has improved its net margin to roughly -9%, but it remains loss-making with negative EBIT and EBITDA margins. Until revenue or collaboration economics support breakeven, recurring operating losses will continue to weaken financial resilience and limit internally funded growth.
Eroding Equity BaseDeclining equity and a negative return on equity of about 31% indicate that ongoing losses are eroding shareholder capital. This weakens the balance-sheet foundation over time and increases the importance of successful development, partnering, or commercialization outcomes.
MacroGenics News
M55 FAQ
What was MacroGenics’s price range in the past 12 months?
Currently, no data Available
What is MacroGenics’s market cap?
MacroGenics’s market cap is CHF170.99M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Nov 04, 2026 which is in 17 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Aug 13, 2026. The company reported CHF0.256 earnings per share for the quarter, beating the consensus estimate of -CHF0.064 by CHF0.32.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.26.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,700,188 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of CHF0.256 in its last earnings report, beating expectations of -CHF0.064. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in CH:M55
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF5.79 (― Upside)
CHF5.79 (― Upside)
Blogger Sentiment
Neutral
CH:M55 Sentiment 75%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
92.30%
12-Months-Change
Fundamentals
Return on Equity
-31.27%
Trailing 12-Months
Asset Growth
40.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.